Current evidence, albeit limited, suggests that esketamine appears to be cognitively safe in adults with treatment-resistant depression and may confer selective improvements, particularly in attention and processing speed, with more variable benefits in memory and executive functioning over sustaine …
In real-world clinical setting, ESK NS produces progressive improvements in depressive symptoms and functioning that often consolidating beyond the induction phase, especially during optimization phase.
Ketamine and esketamine represent mechanistically novel and clinically effective treatments for bipolar depression. Their rapid antidepressant action and low switch liability distinguish them from traditional antidepressants. Esketamine, with its favorable tolerability and intranasal administration, …
Not for nothing, but after 30 years of trying to treat my treatment resistant depression, I'm a little over a month into Spravato (esketamine) treatment and it seems to be the only thing that's made a difference without intolerable side effects. In fact, I don't remember a time in my life ever when I've felt this way. The heaviness has lifted, not to be replaced by temporary mania or numbness, but a sort of objective clearness. I still have meltdowns and lapses, but they are growing fewer and I can better see them coming. I no longer feel trapped by them or inside of them. I feel more like I walk beside them. I hold their hand and try to navigate the world together. When I can. When I can. Sometimes they rush ahead. But my relationship with my depression is changing. We are equals now. I am learning to converse with it instead of letting it dictate the terms.
@PsychedelicInstitute https://mastodon.social/@PsychedelicInstitute/116216070749936835
#MentalHealth #TreatmentResistentDepression #TRD #Spravato #Esketamine
Sponsorship of drug and device studies by the manufacturing company leads to more favorable efficacy results and conclusions than sponsorship by other sources. Our analyses suggest the existence of an industry bias that cannot be explained by standard 'Risk of bias' assessments.
Speaker: Samuel Wilkinson, MD Associate Professor of Psychiatry Yale School of Medicine Activity Directors: Robert Ostroff, MD Sina Nikayin, MD Objectives: 1. To learn the fundamental biological differences between ketamine and esketamine 2. To learn the different ways these drugs are regulated in psychiatry 3. To learn the evidence that has compared the two therapies Disclosures: The Yale School of Medicine implemented mechanisms to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity. All CME staff and content reviewers have no relevant financial relationships with commercial interests to disclose. ACCREDITATION and CREDIT DESIGNATION: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Yale School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Psychedelic Institute Project
J. R. DePriest 
:EA DATA. SF:
Sina Nikayin, MD